ASX RELEASE

22 March 2017

Paradigm Biopharma receives $1.34 million R&D tax incentive rebate

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is pleased to announce that it has received an R&D Tax Incentive rebate of $1.34 million for R&D expenditure undertaken during the 2016 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 45% of eligible expenditure on research and development.

FOR FURTHER INFORMATION PLEASE CONTACT:

Paul Rennie
Director & CEO
Paradigm BioPharmaceuticals Ltd
Level 2, 517 Flinders Lane, Melb, VIC, 3000, AUSTRALIA
ABN: 94 169 346 963
Web: http://paradigmbiopharma.com/
Email: prennie@paradigmbiopharma.com
Mobile International: +61 437 778 300
Mobile (Australia): 0437 778 300